<DOC>
	<DOCNO>NCT01980160</DOCNO>
	<brief_summary>The primary study hypothesis , without increase dos breakthrough medication device intolerance , Nometex™ device wear 5-days beginning day chemotherapy administration woman ovarian advanced endometrial cervical cancer , adjunct standard-of-care anti-emetics , reduce vomit episode , reduce severity nausea . The secondary hypothesis Nometex™ device reduces acute ( Day 1 ) emetic episode , day 1 day 2-5 severity nausea , delay ( day 2-5 ) emetic episode without increase dos breakthrough medication device intolerance .</brief_summary>
	<brief_title>Relief Band Adjunct Antiemetic Therapy Patients Who Receive Mod Highly Emetogenic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>1 . Women ovarian ( include fallopian tube ) advance endometrial cervical cancer 2 . Chemotherapynaïve previous chemotherapy exposure , yet receive first infusion 3 . 18 year age old , provide cognizant informed consent present Helen F. Graham Cancer Center 4 . ECOG Status 02 5 . Standardized Antiemetic Regimen 1 . Preexisting atrisk peripheral neuropathy region device placement 2 . Implanted cardiac pace maker 3 . Nickel metal allergy 4 . Previous experience median nerve/P6 stimulation 5 . Receiving concurrent radiation therapy 6 . Previous participant study exclude future participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>